Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by biggonadson Nov 17, 2022 2:54pm

154 Views

Post# 35108023

AGN progress on DMT clinical stroke research program

Algernon Pharmaceuticals announces that they’ve initiated their DMT clinical stroke research program with their Phase 1 study in the Netherlands. The release today indicates the progress of this clinical trial with the screening of its first subjects for the phase 1 DMT human stroke study. As multiple DMT phase 1 studies have already been conducted, the company expects no serious adverse events or safety issues which will lead to an effective transition into phase 2 acute stroke and rehab studies. https://www.globenewswire.com/news-release/2022/11/16/2557039/0/en/algernon-pharmaceuticals-screens-first-subject-in-phase-1-dmt-human-stroke-study.html

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports